Opinion|Podcasts|March 3, 2025
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Advertisement
Episodes in this series
Advertisement
Related to this article
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
Advertisement
Advertisement
Trending on Urology Times
1
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
2
Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution
3
Three-year data show durable responses with mitomycin intravesical solution
4
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
5